Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $16.67 Consensus PT from Analysts

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $16.67.

A number of research firms have recently commented on ATRA. HC Wainwright restated a "neutral" rating on shares of Atara Biotherapeutics in a report on Wednesday, August 21st. Mizuho raised Atara Biotherapeutics from a "neutral" rating to an "outperform" rating and reduced their price objective for the company from $25.00 to $18.00 in a research note on Friday, August 16th. Canaccord Genuity Group increased their target price on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Finally, TD Cowen raised shares of Atara Biotherapeutics to a "strong-buy" rating in a research report on Friday, November 29th.

Atara Biotherapeutics Price Performance

ATRA stock traded down $0.62 during midday trading on Friday, hitting $10.33. The stock had a trading volume of 96,784 shares, compared to its average volume of 105,220. Atara Biotherapeutics has a 12-month low of $6.50 and a 12-month high of $39.50. The company's 50-day moving average price is $10.54 and its 200 day moving average price is $9.74. The firm has a market cap of $59.50 million, a PE ratio of -0.40 and a beta of 0.55.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same period in the previous year, the business posted ($16.50) earnings per share. As a group, sell-side analysts anticipate that Atara Biotherapeutics will post -12.12 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Atara Biotherapeutics in the second quarter worth $53,000. Cubist Systematic Strategies LLC bought a new stake in Atara Biotherapeutics in the 2nd quarter valued at about $79,000. State Street Corp boosted its stake in Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company's stock valued at $182,000 after purchasing an additional 7,680 shares during the period. FMR LLC grew its position in Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company's stock worth $204,000 after purchasing an additional 7,381 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Atara Biotherapeutics by 9.5% in the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company's stock valued at $380,000 after purchasing an additional 4,043 shares during the period. Institutional investors and hedge funds own 70.90% of the company's stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.